Born 1964. CEO from September 1, 2022.
Education: Holds an MBA from Henley Business School, University of Reading, UK. Management education from the London Business School and Harvard.
Experience: Anders Karlsson has extensive experience in leading operational roles and board work within the Swedish and international life science industry. After being CEO of Novartis’ Norwegian operations 2003-2006, where he among other things was responsible for the commercialization of CNS drugs, he has held the role of CEO at the medical technology companies Absorber, Olerup International, Olerup SSP 2007-2011, and Allenex (Nasdaq Small Cap) 2011-2016. He has also been responsible for the global operations, outside North America, in the US-listed (Nasdaq) diagnostic company CareDx Inc. 2016-2019.
Before joining Umecrine Cognition Anders held the role as CEO för Idogen AB, a cell therapy company listed on Nasdaq First North (2019-2022).
Other current assignments: –
Holdings in the Company: 10,369 shares.
Born 1967. CSO since 2022.
Education: Magnus has a master’s degree in organic chemistry and a Ph.D. in biotechnology from the Royal Institute of Technology in Stockholm and an Executive MBA from Stockholm Business School, Stockholm University.
Experience: Magnus Doverskog has more than 20 years industry experience from discovery and development projects of both small molecules and biologics. Senior positions at Astra Pain Control, Biovitrum AB, and as CEO of IMED AB. Post doctorial research at the European Molecular Biology Laboratory (EMBL) in Heidelberg where he obtained a Marie Curie individual Fellowship. Magnus also held the role as CEO of Umecrine Cognition between 2012-2022.
Other current assignments: –
Holdings in the Company: 10,369 shares.
Born 1968. CFO since 2021.
Education: Hans Christopher has an M.Sc. in Economics from the Stockholm School of Economics.
Experience: Hans Christopher “HC” Toll has previous experience as CFO for companies within several industries since 2004, such as Portescap SA and KIN Group, and currently has consulting assignments for companies such as Cedergrenska AB, EcoBloom Sweden AB, Yabie AB and WeHype Global AB. Furthermore, he has experience from previous listings, and was during 2016 CFO for AIK Fotboll AB when it was listed on NGM, and assisted in the listings of FundedByMe and Cedergrenska AB on Nasdaq First North Growth Market.
Other current assignments: Board member of Livgrenadjärmässen Hotell- Fest- Konferens in Linköping AB, Hydra Consulting AB and HC Toll Control AB
Holdings in the company: –
Born 1957.
Education: Lars holds an MBA from the Stockholm School of Economics.
Experience: Lars Öhman has more than 25 years wide-ranging research and business experience in senior positions at Karo Bio AB and Pharmacia. Proven track record in drug discovery and business development within the pharmaceutical industry. Responsible for in- and out-licensing of drug discovery and development projects to the pharmaceutical industry at Karo Bio during 2004-2012.
Other current assignments: Chairman of the board at Kubera Pharmaceuticals AB, Director of the Board and CBDO at Lipigon Pharmaceuticals AB, CEO at Kubator Therapeutics AB, Director of the Board and Principal at Cordator Life Science AB, CEO at Immunscape AB. Chairman of the board at Omnio AB. Chairman of the Board at Betulaceae Pharmaceuticals AB
Holdings in the company: –